

A W Armstrong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7211989/publications.pdf>

Version: 2024-02-01

135
papers

8,247
citations

94381

37
h-index

51562

86
g-index

145
all docs

145
docs citations

145
times ranked

6401
citing authors

#	ARTICLE	IF	CITATIONS
1	Pathophysiology, Clinical Presentation, and Treatment of Psoriasis. JAMA - Journal of the American Medical Association, 2020, 323, 1945.	3.8	953
2	Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. New England Journal of Medicine, 2015, 373, 1318-1328.	13.9	656
3	Psoriasis prevalence among adults in the United States. Journal of the American Academy of Dermatology, 2014, 70, 512-516.	0.6	650
4	Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. Journal of the American Academy of Dermatology, 2017, 76, 418-431.	0.6	554
5	Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. Journal of the American Academy of Dermatology, 2019, 80, 1029-1072.	0.6	542
6	Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. New England Journal of Medicine, 2016, 375, 422-434.	13.9	530
7	The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutrition and Diabetes, 2012, 2, e54-e54.	1.5	363
8	Undertreatment, Treatment Trends, and Treatment Dissatisfaction Among Patients With Psoriasis and Psoriatic Arthritis in the United States. JAMA Dermatology, 2013, 149, 1180.	2.0	327
9	Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet, The, 2019, 394, 831-839.	6.3	250
10	Quality of Life and Work Productivity Impairment among Psoriasis Patients: Findings from the National Psoriasis Foundation Survey Data 2003-2011. PLoS ONE, 2012, 7, e52935.	1.1	235
11	Managing Patients with Psoriatic Disease: The Diagnosis and Pharmacologic Treatment of Psoriatic Arthritis in Patients with Psoriasis. Drugs, 2014, 74, 423-441.	4.9	209
12	Economic Burden of Psoriasis in the United States. JAMA Dermatology, 2015, 151, 651.	2.0	189
13	US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey. American Journal of Clinical Dermatology, 2016, 17, 87-97.	3.3	173
14	Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet, The, 2021, 397, 487-498.	6.3	139
15	From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis. Journal of the American Academy of Dermatology, 2017, 76, 290-298.	0.6	137
16	Psoriasis and suicidality: A systematic review and meta-analysis. Journal of the American Academy of Dermatology, 2017, 77, 425-440.e2.	0.6	117
17	Bimekizumab versus Adalimumab in Plaque Psoriasis. New England Journal of Medicine, 2021, 385, 130-141.	13.9	114
18	Association Between Atopic Dermatitis and Suicidality. JAMA Dermatology, 2019, 155, 178.	2.0	78

#	ARTICLE	IF	CITATIONS
19	Psoriasis Comorbidities: Results from the National Psoriasis Foundation Surveys 2003 to 2011. <i>Dermatology</i> , 2012, 225, 121-126.	0.9	77
20	Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 936-945.	0.6	71
21	Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study. <i>Journal of Investigative Dermatology</i> , 2019, 139, 2437-2446.e1.	0.3	70
22	Patient-Centered, Direct-Access Online Care for Management of Atopic Dermatitis. <i>JAMA Dermatology</i> , 2015, 151, 154.	2.0	68
23	Clinical Goals and Barriers to Effective Psoriasis Care. <i>Dermatology and Therapy</i> , 2019, 9, 5-18.	1.4	63
24	Teledermatology in the United States: An Update in a Dynamic Era. <i>Telemedicine Journal and E-Health</i> , 2018, 24, 691-697.	1.6	62
25	Anxiety and depression in patients with moderate to severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1940-1949.	1.3	62
26	Metabolomics in psoriatic disease: pilot study reveals metabolite differences in psoriasis and psoriatic arthritis. <i>F1000Research</i> , 2014, 3, 248.	0.8	61
27	Combining Biologic Therapies With Other Systemic Treatments in Psoriasis. <i>JAMA Dermatology</i> , 2015, 151, 432.	2.0	59
28	Anti-tumor necrosis factor agents in sarcoidosis: A systematic review of efficacy and safety. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 1093-1104.	1.6	55
29	Under-Treatment of Patients with Moderate to Severe Psoriasis in the United States: Analysis of Medication Usage with Health Plan Data. <i>Dermatology and Therapy</i> , 2017, 7, 97-109.	1.4	53
30	Effect of appearance-based education compared with health-based education on sunscreen use and knowledge: A randomized controlled trial. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 665-669.	0.6	51
31	Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure. <i>Dermatology and Therapy</i> , 2020, 10, 133-150.	1.4	51
32	Updates on cardiovascular comorbidities associated with psoriatic diseases: epidemiology and mechanisms. <i>Rheumatology International</i> , 2017, 37, 97-105.	1.5	48
33	Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis. <i>JAMA Dermatology</i> , 2016, 152, 661.	2.0	46
34	The International Dermatology Outcome Measures Group: Formation of patient-centered outcome measures in dermatology. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 345-348.	0.6	44
35	Psoriasis and risk of diabetes-associated microvascular and macrovascular complications. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 968-977.e2.	0.6	43
36	National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1704-1716.	0.6	43

#	ARTICLE	IF	CITATIONS
37	Patient perceptions of clear/almost clear skin in moderate-to-severe plaque psoriasis: results of the Clear About Psoriasis worldwide survey. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 2200-2207.	1.3	42
38	Dermatologists in social media: A study on top influencers, posts, and user engagement. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1452-1455.	0.6	42
39	Identifying a Core Domain Set to Assess Psoriasis in Clinical Trials. <i>JAMA Dermatology</i> , 2018, 154, 1137.	2.0	41
40	Set-back versus buried vertical mattress suturing: Results of a randomized blinded trial. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 674-680.	0.6	38
41	Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2*. <i>British Journal of Dermatology</i> , 2021, 185, 1146-1159.	1.4	36
42	Fate of manuscripts declined by the <i>Journal of the American Academy of Dermatology</i> . <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 632-635.	0.6	34
43	Epidemiology of classic and AIDS-related Kaposi's sarcoma in the USA: incidence, survival, and geographical distribution from 1975 to 2005. <i>Epidemiology and Infection</i> , 2013, 141, 200-206.	1.0	29
44	A Review of Health Outcomes in Patients with Psoriasis. <i>Dermatologic Clinics</i> , 2012, 30, 61-72.	1.0	28
45	Public perception of dermatologists and comparison with other medical specialties: Results from a national survey. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 875-881.	0.6	26
46	Effect of Adhesive Strips and Dermal Sutures vs Dermal Sutures Only on Wound Closure. <i>JAMA Dermatology</i> , 2015, 151, 862.	2.0	26
47	Secukinumab in the Treatment of Palmoplantar, Nail, Scalp, and Pustular Psoriasis. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2016, 9, S12-S16.	0.1	26
48	Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials. <i>British Journal of Dermatology</i> , 2019, 180, 306-314.	1.4	25
49	Direct-Access Online Care for the Management of Atopic Dermatitis: A Randomized Clinical Trial Examining Patient Quality of Life. <i>Telemedicine Journal and E-Health</i> , 2017, 23, 726-732.	1.6	24
50	Real-world health outcomes in adults with moderate-to-severe psoriasis in the United States: a population study using electronic health records to examine patient-perceived treatment effectiveness, medication use, and healthcare resource utilization. <i>BMC Dermatology</i> , 2018, 18, 4.	2.1	24
51	Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 881-890.	3.3	24
52	Real-world utilization patterns of systemic immunosuppressants among US adult patients with atopic dermatitis. <i>PLoS ONE</i> , 2019, 14, e0210517.	1.1	22
53	POS1042...EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, COMPARED WITH PLACEBO AND APREMILAST IN MODERATE TO SEVERE PLAQUE PSORIASIS: RESULTS FROM THE PHASE 3 POETYPK PSO-1 STUDY. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 795.1-796.	0.5	21
54	Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1733-1741.	1.3	20

#	ARTICLE	IF	CITATIONS
55	Validation of psychometric properties and development of response criteria for the psoriasis symptoms and signs diary (PSSD): results from a phase 3 clinical trial. <i>Journal of Dermatological Treatment</i> , 2019, 30, 27-34.	1.1	20
56	The International Dermatology Outcome Measures Initiative as Applied to Psoriatic Disease Outcomes: A Report from the GRAPPA 2013 Meeting. <i>Journal of Rheumatology</i> , 2014, 41, 1227-1229.	1.0	18
57	Psoriasis Provoked or Exacerbated by Medications. <i>JAMA Dermatology</i> , 2014, 150, 963.	2.0	18
58	Engaging but inaccurate: A cross-sectional analysis of acne videos on social media from non-health care sources. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 610-612.	0.6	18
59	Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2317-2324.	1.1	17
60	The Use of Biologics During the COVID-19 Pandemic. <i>Dermatologic Clinics</i> , 2021, 39, 545-553.	1.0	17
61	Managing Patients With Psoriasis in the Busy Clinic. <i>Journal of Cutaneous Medicine and Surgery</i> , 2016, 20, 196-206.	0.6	16
62	Psoriasis, electrocardiographic characteristics, and incidence of atrial fibrillation. <i>Archives of Dermatological Research</i> , 2013, 305, 891-897.	1.1	15
63	Effects of online care on functional and psychological outcomes in patients with psoriasis: A randomized controlled trial. <i>Journal of the American Academy of Dermatology</i> , 2023, 88, 364-370.	0.6	15
64	Real-world experience of calcipotriene and betamethasone dipropionate foam 0.005%/0.064% in the treatment of adults with psoriasis in the United States. <i>Journal of Dermatological Treatment</i> , 2019, 30, 454-460.	1.1	15
65	Effect of Automated Online Counseling on Clinical Outcomes and Quality of Life Among Adolescents With Acne Vulgaris. <i>JAMA Dermatology</i> , 2015, 151, 970.	2.0	13
66	Comparison of mental health outcomes among adults with psoriasis on biologic versus oral therapies: a population-based study. <i>Journal of Dermatological Treatment</i> , 2019, 30, 135-140.	1.1	11
67	Association between atopic dermatitis and conjunctivitis in adults: a population-based study in the United States. <i>Journal of Dermatological Treatment</i> , 2021, 32, 455-459.	1.1	11
68	Economic Burden of Chronic Hand Eczema: A Review. <i>American Journal of Clinical Dermatology</i> , 2022, 23, 287-300.	3.3	11
69	Are Your Patients Satisfied A Systematic Review of Treatment Satisfaction Measures in Psoriasis. <i>Dermatology</i> , 2018, 234, 157-165.	0.9	10
70	Guselkumab improves work productivity in patients with moderate-to-severe psoriasis with or without depression and anxiety: results from the VOYAGE 2 comparator study versus adalimumab. <i>Journal of Dermatological Treatment</i> , 2020, 31, 617-623.	1.1	10
71	Defining Outcome Measures for Psoriasis: The IDEOM Report from the GRAPPA 2016 Annual Meeting. <i>Journal of Rheumatology</i> , 2017, 44, 701-702.	1.0	9
72	Where you live matters: Regional differences in health care resource use for psoriasis in the United States. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 1360-1367.	0.6	9

#	ARTICLE	IF	CITATIONS
73	Updates in Rosacea: Epidemiology, Risk Factors, and Management Strategies. <i>Current Dermatology Reports</i> , 2014, 3, 23-28.	1.1	8
74	Electroabrasion vs. manual dermabrasion: a randomized, double-blind, comparative effectiveness trial. <i>British Journal of Dermatology</i> , 2014, 171, 124-129.	1.4	8
75	Effectiveness of a novel interactive health care education tool on clinical outcomes and quality of life in acne patients: A randomized controlled pilot study. <i>Journal of Dermatological Treatment</i> , 2015, 26, 435-439.	1.1	8
76	International Dermatology Outcome Measures Initiative as Applied to Psoriatic Disease Outcomes: An Update. <i>Journal of Rheumatology</i> , 2016, 43, 959-960.	1.0	8
77	Strategies to maximize clinical efficiency while maintaining patient safety during the COVID-19 pandemic: an interview-based study from private practice dermatologists. <i>Journal of Dermatological Treatment</i> , 2020, , 1-4.	1.1	8
78	Report of the Skin Research Working Groups From the GRAPPA 2020 Annual Meeting. <i>Journal of Rheumatology</i> , 2021, , jrheum.201668.	1.0	8
79	Psoriasis and Psoriatic Arthritis Educational Initiatives: An Update from the 2013 GRAPPA Annual Meeting. <i>Journal of Rheumatology</i> , 2014, 41, 1240-1243.	1.0	7
80	A provider global assessment quality measure for clinical practice for inflammatory skin disorders. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 823-828.	0.6	7
81	Suicidality among psoriasis patients: a critical evidence synthesis. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2019, 154, 56-63.	0.8	7
82	Brodalumab to the Rescue: Efficacy and Safety of Brodalumab in Patients with Psoriasis and Prior Exposure or Inadequate Response to Biologics. <i>Dermatology and Therapy</i> , 2020, 10, 615-621.	1.4	7
83	Work/study productivity gain and associated indirect cost savings with guselkumab compared with adalimumab in moderate-to-severe psoriasis: results from the VOYAGE 1 study. <i>Journal of Dermatological Treatment</i> , 2022, 33, 278-283.	1.1	6
84	Investigator and Patient Global Assessment Measures for Psoriasis Clinical Trials: A Systematic Review on Measurement Properties from the International Dermatology Outcome Measures (IDEOM) Initiative. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 323-338.	3.3	6
85	Examination of Treatment Satisfaction Instruments in Psoriasis: 2017 Results from the Psoriasis Working Group of the International Dermatology Outcome Measures (IDEOM). <i>Dermatology</i> , 2021, 237, 151-157.	0.9	6
86	Reply to: "Comment on "Dermatologists in social media: A study on top influencers, posts, and user engagement"™": <i>Journal of the American Academy of Dermatology</i> , 2022, 86, e51.	0.6	6
87	Does location matter? Geographic variations in healthcare resource use for atopic dermatitis in the United States. <i>Journal of Dermatological Treatment</i> , 2021, 32, 314-320.	1.1	6
88	Follicular Eruption on Arms and Legs"Quiz Case. <i>Archives of Dermatology</i> , 2008, 144, 1509-14.	1.7	5
89	Outcomes Research in Psoriasis and Psoriatic Arthritis Using Large Databases and Research Networks: A Report from the GRAPPA 2013 Annual Meeting. <i>Journal of Rheumatology</i> , 2014, 41, 1233-1236.	1.0	5
90	Cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe psoriasis in the United States. <i>Journal of Dermatological Treatment</i> , 2022, 33, 740-748.	1.1	5

#	ARTICLE	IF	CITATIONS
91	Calcipotriol/betamethasone dipropionate foam demonstrates comparable efficacy to clinical trial data in the real world, improves patient satisfaction and is cost-effective. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 28-34.	1.3	5
92	Differences in health care resource utilization and costs for keratinocyte carcinoma among racioethnic groups: A population-based study. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 373-378.	0.6	5
93	Bullous Dermatoses and Depression. <i>JAMA Dermatology</i> , 2021, 157, 1487.	2.0	5
94	Assessing Skin Biopsy Rates for Histologic Findings Indicative of Nonpathological Cutaneous Disease. <i>Dermatologic Surgery</i> , 2019, 45, 640-649.	0.4	4
95	Development of the Psoriasis Symptoms Scale (PSS) in patients with moderate-to-severe psoriasis: qualitative and quantitative analyses. <i>Journal of Dermatological Treatment</i> , 2020, 31, 452-459.	1.1	4
96	An association between hidradenitis suppurativa and HIV. <i>British Journal of Dermatology</i> , 2020, 182, 490-491.	1.4	4
97	Association Between the Mental Health of Patients With Psoriasis and Their Satisfaction With Physicians. <i>JAMA Dermatology</i> , 2020, 156, 754.	2.0	4
98	International Dermatology Outcome Measures (IDEOM): Report from the 2020 Annual Meeting. <i>Dermatology</i> , 2022, 238, 430-437.	0.9	4
99	Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic Dermatitis. <i>Dermatology and Therapy</i> , 2021, 11, 2147-2157.	1.4	4
100	Updates on treatment guidelines for psoriasis, atopic dermatitis (eczema), hidradenitis suppurativa, and acne/rosacea during the COVID-19 pandemic. <i>Dermatology Online Journal</i> , 2020, 26, .	0.2	4
101	Who sees you matters: a population study examining topical corticosteroid prescribing patterns between primary care providers and dermatologists for atopic dermatitis. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1507-1510.	1.1	3
102	Words matter: a randomized controlled study evaluating the impact of decision framing on treatment preferences in adults with psoriasis and psoriatic arthritis. <i>British Journal of Dermatology</i> , 2021, 184, 971-973.	1.4	3
103	Mental health outcomes and their association to race and ethnicity in acne patients: A population-based study. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 140-142.	0.6	3
104	Mental health outcomes in White patients versus patients with skin of color with psoriasis. <i>Dermatology Online Journal</i> , 2021, 27, .	0.2	3
105	Comparison of physical and mental functioning among moderate-to-severe psoriasis patients on biologic versus oral therapy. <i>Archives of Dermatological Research</i> , 2019, 311, 453-460.	1.1	2
106	Defining drug-free remission of skin disease in patients with plaque psoriasis. <i>British Journal of Dermatology</i> , 2020, 182, 1484-1487.	1.4	2
107	Language proficiency and biologics access: a population study of psoriasis patients in the United States. <i>Journal of Dermatological Treatment</i> , 2020, , 1-5.	1.1	2
108	Response to Letter to the Editor "Reply to" Dermatologists in Social Media: A Study on Top Influencers, Posts, and User Engagement. <i>Dermatologist Influencers on TikTok</i> . <i>Journal of the American Academy of Dermatology</i> , 2021, , .	0.6	2

#	ARTICLE	IF	CITATIONS
109	Screening Recommendations for Chlamydia and Gonorrhea. <i>JAMA Dermatology</i> , 2015, 151, 1014.	2.0	1
110	Patient-Reported Outcome Measures for Pediatric Psoriasis: A Systematic Review and Critical Appraisal from International Dermatology Outcome Measures (IDEOM). <i>Dermatology</i> , 2018, 234, 112-119.	0.9	1
111	Exploring Mental Disorders in Patients With Skin Diseases. <i>JAMA Dermatology</i> , 2019, 155, 660.	2.0	1
112	Report from the International Dermatology Outcome Measures Initiative. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2020, 20, S80-S83.	0.8	1
113	GRAPPA Trainee Symposium 2020: A Summary of Oral and Poster Presentations. <i>Journal of Rheumatology</i> , 2021, , jrheum.201670.	1.0	1
114	AB0528â€¦.COMPARABLE SAFETY PROFILE OF GUSELKUMAB IN PSORIATIC ARTHRITIS AND PSORIASIS: RESULTS FROM PHASE 3 TRIALS THROUGH 1 YEAR. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1293-1294.	0.5	1
115	A Blueprint for the Conduct of Large, Multisite Trials in Telemedicine. <i>Journal of Medical Internet Research</i> , 2021, 23, e29511.	2.1	1
116	Chronic spontaneous urticaria: a 16-year analysis of pediatric patient demographics, treatment patterns, and comorbidities. <i>Dermatology Online Journal</i> , 2021, 27, .	0.2	1
117	Topical opioid use in dermatologic disease: A systematic review. <i>Dermatologic Therapy</i> , 2021, 34, e15150.	0.8	1
118	Rosacea videos on social media: A comparison of accuracy, quality, and viewer engagement. <i>Dermatology Online Journal</i> , 2021, 27, .	0.2	1
119	Response to Letter to the Editor commenting on: "Dermatologists in social media: A study on top influencers, posts, and user engagement" <i>Journal of the American Academy of Dermatology</i> , 2021, 84, e165.	0.6	0
120	Differences in wage earnings between psoriasis patients on biologics versus those on oral therapies: a population-based study in the United States. <i>Journal of Dermatological Treatment</i> , 2021, 32, 440-445.	1.1	0
121	Pemphigus and bullous pemphigoid in the United States: a 21-year analysis of patient characteristics, treatment patterns, and comorbidities. <i>Journal of Dermatological Treatment</i> , 2021, , 1-3.	1.1	0
122	Childhood atopic dermatitis: outpatient visit trends, demographics, and topical agents in the United States, 1995â€"2015. <i>International Journal of Dermatology</i> , 2021, 60, e423-e424.	0.5	0
123	Opiate use in dermatology: A population-based study using the National Ambulatory Medical Care Survey in the United States. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 174-176.	0.6	0
124	Chronic spontaneous urticaria in the United States: patient characteristics and treatment patterns. <i>International Journal of Dermatology</i> , 2022, 61, .	0.5	0
125	Trichotillomania in the United States: An epidemiologic study of patient characteristics, comorbidities, and treatment patterns. <i>Dermatology Online Journal</i> , 2021, 27, .	0.2	0
126	Validation of Patient-Reported Psoriasis Diagnosis from a Global Online Research Network. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2539-2541.	0.3	0

#	ARTICLE	IF	CITATIONS
127	Defining Psoriasis Remission Based on Histopathologic and Molecular Criteria: A Systematic Literature Review. <i>Journal of Investigative Dermatology</i> , 2022, 142, 2026-2029.e4.	0.3	0
128	Re-Classification of Psoriasis Severity: Perspectives and Controversy. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2022, 7, 7-8.	0.3	0
129	An unusual spiculated presentation of follicular porokeratosis. <i>Dermatology Online Journal</i> , 2019, 25, .	0.2	0
130	Report of the Skin Research Working Groups from the GRAPPA 2021 Annual Meeting. <i>Journal of Rheumatology</i> , 2022, , jrheum.211328.	1.0	0
131	Are we contributing to the opioid epidemic? A systematic review on systemic opioid use in dermatology. <i>International Journal of Dermatology</i> , 2021, , .	0.5	0
132	2021 GRAPPA Trainee Symposium: A Summary of Oral and Poster Presentations. <i>Journal of Rheumatology</i> , 2022, , jrheum.211318.	1.0	0
133	The psoriasis glycome: differential expression of cholesterol particle glycans and IgA glycans linked to disease severity. <i>Journal of Investigative Dermatology</i> , 2022, , .	0.3	0
134	2021 GRAPPA Meet the Experts Session: A Summary of Presentations.. <i>Journal of Rheumatology</i> , 2022, , .	1.0	0
135	Public Perception of SARS-CoV-2 Vaccines Among Psoriasis Patients in Social Media: Content, Sentiment, and Engagement Analysis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 0, , 247553032211100.	0.3	0